Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03094663 · ClinicalTrials.gov registry record · Phase 4
Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)
A Phase 4 study, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 86
- Enrollment target
NCT03094663 is a Phase 4 study that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 86 participants.
The verdict
NCT03094663, a Phase 4 study, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 86 participants
- Enrollment target
Study Summary
A comparison of two pain control methods - the combination of Adductor Canal Block (ACB)/Periarticular Injection (PAI)/Infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (IPACK) versus the Periarticular Injection (PAI) - in patients undergoing total knee arthroplasty. Primary outcome is NRS pain scores with ambulation on postoperative day one (24 hours post-block administration).
Interventions
- DRUG Methylprednisolone
- DRUG Cefazolin
- DRUG Bupivacaine with epinephrine
- DEVICE 8 MHz. Chiba needle
- DRUG Bupivacaine with Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2018-09-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03094663
The ClinicalTrials.gov registry entry for NCT03094663 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Methylprednisolone is the first listed.
NCT03094663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03094663 about?
NCT03094663 is a clinical study titled "Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)". A comparison of two pain control methods - the combination of Adductor Canal Block (ACB)/Periarticular Injection (PAI)/Infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (IPACK) versus the Periarticular Injection (PAI) - in patients undergoing total kne...
What is the current status of trial NCT03094663?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. The study started on 2017-02-28. Estimated completion is 2018-09-01.
What interventions are being tested in trial NCT03094663?
The interventions under investigation include: Methylprednisolone (DRUG), Cefazolin (DRUG), Bupivacaine with epinephrine (DRUG), 8 MHz. Chiba needle (DEVICE), Bupivacaine with Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT03094663?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.